The global Neurodegenerative Disease market is projected to grow from US$ 7239.3 million in 2024 to US$ 8704 million by 2030, at a Compound Annual Growth Rate (CAGR) of 3.1% during the forecast period.

Neurodegenerative Disease Market

Neurodegenerative diseases are a group of disorders characterized by the progressive degeneration of the structure and function of the nervous system, leading to cognitive and motor impairments. Examples include Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).

Market Analysis and Insights: Global Neurodegenerative Disease Market

The market for neurodegenerative disease treatments and management is driven by the increasing prevalence of these diseases, particularly with an aging population. The market's growth is also influenced by the demand for disease-modifying therapies and symptom management options to improve the quality of life for patients.

Report Covers:

This report presents an overview of global market for Neurodegenerative Disease market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Neurodegenerative Disease, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Neurodegenerative Disease, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Neurodegenerative Disease revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Neurodegenerative Disease market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Neurodegenerative Disease revenue, projected growth trends, production technology, application and end-user industry.

Market Segmentation

Scope of Neurodegenerative Disease Market Report

Report Metric	Details
Report Name	Neurodegenerative Disease Market
Accounted market size in 2024	US$ 7239.3 million
Forecasted market size in 2030	US$ 8704 million
CAGR	3.1
Base Year	2024
Forecasted years	2024 - 2030
Segment by Type	NMDA SSRIs Dopamine Inhibitors
Segment by Application	Parkinson’s Disease Huntington Disease Amyotrophic Lateral Sclerosis Alzheimer’s Disease
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Novartis, Pfizer, Merck Serono, Biogen Idec, TEVA, UCB, Boehringer Ingelheim, Sanofi, GlaxoSmithKline, Livzon Pharmaceutical, Haisco Pharmaceutical, Jingxin Pharmaceutical, Dongcheng Biochemicals, Hisun Pharmaceutical, Luye Pharma, Ark Pharmaceutical, Kanghong Pharmaceutical, Huahai Pharmaceutical, BORA PHARMACEUTICALS
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Neurodegenerative Disease in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neurodegenerative Disease companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neurodegenerative Disease revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

FAQ for this report

How fast is Neurodegenerative Disease Market growing?

Ans: The Neurodegenerative Disease Market witnessing a CAGR of 3.1 during the forecast period 2024-2030.

What is the Neurodegenerative Disease Market size in 2030?

Ans: The Neurodegenerative Disease Market size in 2030 will be US$ 8704 million.

Who are the main players in the Neurodegenerative Disease Market report?

Ans: The main players in the Neurodegenerative Disease Market are Novartis, Pfizer, Merck Serono, Biogen Idec, TEVA, UCB, Boehringer Ingelheim, Sanofi, GlaxoSmithKline, Livzon Pharmaceutical, Haisco Pharmaceutical, Jingxin Pharmaceutical, Dongcheng Biochemicals, Hisun Pharmaceutical, Luye Pharma, Ark Pharmaceutical, Kanghong Pharmaceutical, Huahai Pharmaceutical, BORA PHARMACEUTICALS

What are the Application segmentation covered in the Neurodegenerative Disease Market report?

Ans: The Applications covered in the Neurodegenerative Disease Market report are Parkinson’s Disease, Huntington Disease, Amyotrophic Lateral Sclerosis, Alzheimer’s Disease

What are the Type segmentation covered in the Neurodegenerative Disease Market report?

Ans: The Types covered in the Neurodegenerative Disease Market report are NMDA, SSRIs, Dopamine Inhibitors

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Neurodegenerative Disease Market Size Growth Rate by Type, 2019 VS 2023 VS 2030

1.2.2 NMDA

1.2.3 SSRIs

1.2.4 Dopamine Inhibitors

1.3 Market by Application

1.3.1 Global Neurodegenerative Disease Market Size Growth Rate by Application, 2019 VS 2023 VS 2030

1.3.2 Parkinson’s Disease

1.3.3 Huntington Disease

1.3.4 Amyotrophic Lateral Sclerosis

1.3.5 Alzheimer’s Disease

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Neurodegenerative Disease Market Perspective (2019-2030)

2.2 Global Neurodegenerative Disease Growth Trends by Region

2.2.1 Neurodegenerative Disease Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Neurodegenerative Disease Historic Market Size by Region (2019-2024)

2.2.3 Neurodegenerative Disease Forecasted Market Size by Region (2025-2030)

2.3 Neurodegenerative Disease Market Dynamics

2.3.1 Neurodegenerative Disease Industry Trends

2.3.2 Neurodegenerative Disease Market Drivers

2.3.3 Neurodegenerative Disease Market Challenges

2.3.4 Neurodegenerative Disease Market Restraints

3 Competition Landscape by Key Players

3.1 Global Revenue Neurodegenerative Disease by Players

3.1.1 Global Neurodegenerative Disease Revenue by Players (2019-2024)

3.1.2 Global Neurodegenerative Disease Revenue Market Share by Players (2019-2024)

3.2 Global Neurodegenerative Disease Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players of Neurodegenerative Disease, Ranking by Revenue, 2022 VS 2023 VS 2024

3.4 Global Neurodegenerative Disease Market Concentration Ratio

3.4.1 Global Neurodegenerative Disease Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Disease Revenue in 2023

3.5 Global Key Players of Neurodegenerative Disease Head office and Area Served

3.6 Global Key Players of Neurodegenerative Disease, Product and Application

3.7 Global Key Players of Neurodegenerative Disease, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Neurodegenerative Disease Breakdown Data by Type

4.1 Global Neurodegenerative Disease Historic Market Size by Type (2019-2024)

4.2 Global Neurodegenerative Disease Forecasted Market Size by Type (2025-2030)

5 Neurodegenerative Disease Breakdown Data by Application

5.1 Global Neurodegenerative Disease Historic Market Size by Application (2019-2024)

5.2 Global Neurodegenerative Disease Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Neurodegenerative Disease Market Size (2019-2030)

6.2 North America Neurodegenerative Disease Market Size by Type

6.2.1 North America Neurodegenerative Disease Market Size by Type (2019-2024)

6.2.2 North America Neurodegenerative Disease Market Size by Type (2025-2030)

6.2.3 North America Neurodegenerative Disease Market Share by Type (2019-2030)

6.3 North America Neurodegenerative Disease Market Size by Application

6.3.1 North America Neurodegenerative Disease Market Size by Application (2019-2024)

6.3.2 North America Neurodegenerative Disease Market Size by Application (2025-2030)

6.3.3 North America Neurodegenerative Disease Market Share by Application (2019-2030)

6.4 North America Neurodegenerative Disease Market Size by Country

6.4.1 North America Neurodegenerative Disease Market Size by Country: 2019 VS 2023 VS 2030

6.4.2 North America Neurodegenerative Disease Market Size by Country (2019-2024)

6.4.3 North America Neurodegenerative Disease Market Size by Country (2025-2030)

6.4.4 United States

6.4.5 Canada

7 Europe

7.1 Europe Neurodegenerative Disease Market Size (2019-2030)

7.2 Europe Neurodegenerative Disease Market Size by Type

7.2.1 Europe Neurodegenerative Disease Market Size by Type (2019-2024)

7.2.2 Europe Neurodegenerative Disease Market Size by Type (2025-2030)

7.2.3 Europe Neurodegenerative Disease Market Share by Type (2019-2030)

7.3 Europe Neurodegenerative Disease Market Size by Application

7.3.1 Europe Neurodegenerative Disease Market Size by Application (2019-2024)

7.3.2 Europe Neurodegenerative Disease Market Size by Application (2025-2030)

7.3.3 Europe Neurodegenerative Disease Market Share by Application (2019-2030)

7.4 Europe Neurodegenerative Disease Market Size by Country

7.4.1 Europe Neurodegenerative Disease Market Size by Country: 2019 VS 2023 VS 2030

7.4.2 Europe Neurodegenerative Disease Market Size by Country (2019-2024)

7.4.3 Europe Neurodegenerative Disease Market Size by Country (2025-2030)

7.4.3 Germany

7.4.4 France

7.4.5 U.K.

7.4.6 Italy

7.4.7 Russia

7.4.8 Nordic Countries

8 China

8.1 China Neurodegenerative Disease Market Size (2019-2030)

8.2 China Neurodegenerative Disease Market Size by Type

8.2.1 China Neurodegenerative Disease Market Size by Type (2019-2024)

8.2.2 China Neurodegenerative Disease Market Size by Type (2025-2030)

8.2.3 China Neurodegenerative Disease Market Share by Type (2019-2030)

8.3 China Neurodegenerative Disease Market Size by Application

8.3.1 China Neurodegenerative Disease Market Size by Application (2019-2024)

8.3.2 China Neurodegenerative Disease Market Size by Application (2025-2030)

8.3.3 China Neurodegenerative Disease Market Share by Application (2019-2030)

9 Asia (excluding China)

9.1 Asia Neurodegenerative Disease Market Size (2019-2030)

9.2 Asia Neurodegenerative Disease Market Size by Type

9.2.1 Asia Neurodegenerative Disease Market Size by Type (2019-2024)

9.2.2 Asia Neurodegenerative Disease Market Size by Type (2025-2030)

9.2.3 Asia Neurodegenerative Disease Market Share by Type (2019-2030)

9.3 Asia Neurodegenerative Disease Market Size by Application

9.3.1 Asia Neurodegenerative Disease Market Size by Application (2019-2024)

9.3.2 Asia Neurodegenerative Disease Market Size by Application (2025-2030)

9.3.3 Asia Neurodegenerative Disease Market Share by Application (2019-2030)

9.4 Asia Neurodegenerative Disease Market Size by Region

9.4.1 Asia Neurodegenerative Disease Market Size by Region: 2019 VS 2023 VS 2030

9.4.2 Asia Neurodegenerative Disease Market Size by Region (2019-2024)

9.4.3 Asia Neurodegenerative Disease Market Size by Region (2025-2030)

9.4.4 Japan

9.4.5 South Korea

9.4.6 China Taiwan

9.4.7 Southeast Asia

9.4.8 India

9.4.9 Australia

10 Middle East, Africa, and Latin America

10.1 Middle East, Africa, and Latin America Neurodegenerative Disease Market Size (2019-2030)

10.2 Middle East, Africa, and Latin America Neurodegenerative Disease Market Size by Type

10.2.1 Middle East, Africa, and Latin America Neurodegenerative Disease Market Size by Type (2019-2024)

10.2.2 Middle East, Africa, and Latin America Neurodegenerative Disease Market Size by Type (2025-2030)

10.2.3 Middle East, Africa, and Latin America Neurodegenerative Disease Market Share by Type (2019-2030)

10.3 Middle East, Africa, and Latin America Neurodegenerative Disease Market Size by Application

10.3.1 Middle East, Africa, and Latin America Neurodegenerative Disease Market Size by Application (2019-2024)

10.3.2 Middle East, Africa, and Latin America Neurodegenerative Disease Market Size by Application (2025-2030)

10.3.3 Middle East, Africa, and Latin America Neurodegenerative Disease Market Share by Application (2019-2030)

10.4 Middle East, Africa, and Latin America Neurodegenerative Disease Market Size by Country

10.4.1 Middle East, Africa, and Latin America Neurodegenerative Disease Market Size by Country: 2019 VS 2023 VS 2030

10.4.2 Middle East, Africa, and Latin America Neurodegenerative Disease Market Size by Country (2019-2024)

10.4.3 Middle East, Africa, and Latin America Neurodegenerative Disease Market Size by Country (2025-2030)

10.4.4 Brazil

10.4.5 Mexico

10.4.6 Turkey

10.4.7 Saudi Arabia

10.4.8 Israel

10.4.9 GCC Countries

11 Key Players Profiles

11.1 Novartis

11.1.1 Novartis Company Details

11.1.2 Novartis Business Overview

11.1.3 Novartis Neurodegenerative Disease Introduction

11.1.4 Novartis Revenue in Neurodegenerative Disease Business (2019-2024)

11.1.5 Novartis Recent Developments

11.2 Pfizer

11.2.1 Pfizer Company Details

11.2.2 Pfizer Business Overview

11.2.3 Pfizer Neurodegenerative Disease Introduction

11.2.4 Pfizer Revenue in Neurodegenerative Disease Business (2019-2024)

11.2.5 Pfizer Recent Developments

11.3 Merck Serono

11.3.1 Merck Serono Company Details

11.3.2 Merck Serono Business Overview

11.3.3 Merck Serono Neurodegenerative Disease Introduction

11.3.4 Merck Serono Revenue in Neurodegenerative Disease Business (2019-2024)

11.3.5 Merck Serono Recent Developments

11.4 Biogen Idec

11.4.1 Biogen Idec Company Details

11.4.2 Biogen Idec Business Overview

11.4.3 Biogen Idec Neurodegenerative Disease Introduction

11.4.4 Biogen Idec Revenue in Neurodegenerative Disease Business (2019-2024)

11.4.5 Biogen Idec Recent Developments

11.5 TEVA

11.5.1 TEVA Company Details

11.5.2 TEVA Business Overview

11.5.3 TEVA Neurodegenerative Disease Introduction

11.5.4 TEVA Revenue in Neurodegenerative Disease Business (2019-2024)

11.5.5 TEVA Recent Developments

11.6 UCB

11.6.1 UCB Company Details

11.6.2 UCB Business Overview

11.6.3 UCB Neurodegenerative Disease Introduction

11.6.4 UCB Revenue in Neurodegenerative Disease Business (2019-2024)

11.6.5 UCB Recent Developments

11.7 Boehringer Ingelheim

11.7.1 Boehringer Ingelheim Company Details

11.7.2 Boehringer Ingelheim Business Overview

11.7.3 Boehringer Ingelheim Neurodegenerative Disease Introduction

11.7.4 Boehringer Ingelheim Revenue in Neurodegenerative Disease Business (2019-2024)

11.7.5 Boehringer Ingelheim Recent Developments

11.8 Sanofi

11.8.1 Sanofi Company Details

11.8.2 Sanofi Business Overview

11.8.3 Sanofi Neurodegenerative Disease Introduction

11.8.4 Sanofi Revenue in Neurodegenerative Disease Business (2019-2024)

11.8.5 Sanofi Recent Developments

11.9 GlaxoSmithKline

11.9.1 GlaxoSmithKline Company Details

11.9.2 GlaxoSmithKline Business Overview

11.9.3 GlaxoSmithKline Neurodegenerative Disease Introduction

11.9.4 GlaxoSmithKline Revenue in Neurodegenerative Disease Business (2019-2024)

11.9.5 GlaxoSmithKline Recent Developments

11.10 Livzon Pharmaceutical

11.10.1 Livzon Pharmaceutical Company Details

11.10.2 Livzon Pharmaceutical Business Overview

11.10.3 Livzon Pharmaceutical Neurodegenerative Disease Introduction

11.10.4 Livzon Pharmaceutical Revenue in Neurodegenerative Disease Business (2019-2024)

11.10.5 Livzon Pharmaceutical Recent Developments

11.11 Haisco Pharmaceutical

11.11.1 Haisco Pharmaceutical Company Details

11.11.2 Haisco Pharmaceutical Business Overview

11.11.3 Haisco Pharmaceutical Neurodegenerative Disease Introduction

11.11.4 Haisco Pharmaceutical Revenue in Neurodegenerative Disease Business (2019-2024)

11.11.5 Haisco Pharmaceutical Recent Developments

11.12 Jingxin Pharmaceutical

11.12.1 Jingxin Pharmaceutical Company Details

11.12.2 Jingxin Pharmaceutical Business Overview

11.12.3 Jingxin Pharmaceutical Neurodegenerative Disease Introduction

11.12.4 Jingxin Pharmaceutical Revenue in Neurodegenerative Disease Business (2019-2024)

11.12.5 Jingxin Pharmaceutical Recent Developments

11.13 Dongcheng Biochemicals

11.13.1 Dongcheng Biochemicals Company Details

11.13.2 Dongcheng Biochemicals Business Overview

11.13.3 Dongcheng Biochemicals Neurodegenerative Disease Introduction

11.13.4 Dongcheng Biochemicals Revenue in Neurodegenerative Disease Business (2019-2024)

11.13.5 Dongcheng Biochemicals Recent Developments

11.14 Hisun Pharmaceutical

11.14.1 Hisun Pharmaceutical Company Details

11.14.2 Hisun Pharmaceutical Business Overview

11.14.3 Hisun Pharmaceutical Neurodegenerative Disease Introduction

11.14.4 Hisun Pharmaceutical Revenue in Neurodegenerative Disease Business (2019-2024)

11.14.5 Hisun Pharmaceutical Recent Developments

11.15 Luye Pharma

11.15.1 Luye Pharma Company Details

11.15.2 Luye Pharma Business Overview

11.15.3 Luye Pharma Neurodegenerative Disease Introduction

11.15.4 Luye Pharma Revenue in Neurodegenerative Disease Business (2019-2024)

11.15.5 Luye Pharma Recent Developments

11.16 Ark Pharmaceutical

11.16.1 Ark Pharmaceutical Company Details

11.16.2 Ark Pharmaceutical Business Overview

11.16.3 Ark Pharmaceutical Neurodegenerative Disease Introduction

11.16.4 Ark Pharmaceutical Revenue in Neurodegenerative Disease Business (2019-2024)

11.16.5 Ark Pharmaceutical Recent Developments

11.17 Kanghong Pharmaceutical

11.17.1 Kanghong Pharmaceutical Company Details

11.17.2 Kanghong Pharmaceutical Business Overview

11.17.3 Kanghong Pharmaceutical Neurodegenerative Disease Introduction

11.17.4 Kanghong Pharmaceutical Revenue in Neurodegenerative Disease Business (2019-2024)

11.17.5 Kanghong Pharmaceutical Recent Developments

11.18 Huahai Pharmaceutical

11.18.1 Huahai Pharmaceutical Company Details

11.18.2 Huahai Pharmaceutical Business Overview

11.18.3 Huahai Pharmaceutical Neurodegenerative Disease Introduction

11.18.4 Huahai Pharmaceutical Revenue in Neurodegenerative Disease Business (2019-2024)

11.18.5 Huahai Pharmaceutical Recent Developments

11.19 BORA PHARMACEUTICALS

11.19.1 BORA PHARMACEUTICALS Company Details

11.19.2 BORA PHARMACEUTICALS Business Overview

11.19.3 BORA PHARMACEUTICALS Neurodegenerative Disease Introduction

11.19.4 BORA PHARMACEUTICALS Revenue in Neurodegenerative Disease Business (2019-2024)

11.19.5 BORA PHARMACEUTICALS Recent Developments

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Livzon Pharmaceutical

Haisco Pharmaceutical

JINGXIN PHARMACEUTICAL

Dongcheng Biochemicals

Hisun Pharmaceutical

Luye Pharma

Ark Pharmaceutical

Kanghong Pharmaceutical

Huahai Pharmaceutical

BORA PHARMACEUTICALS

List of Tables

Table 1. Global Neurodegenerative Disease Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030

Table 2. Key Players of NMDA

Table 3. Key Players of SSRIs

Table 4. Key Players of Dopamine Inhibitors

Table 5. Global Neurodegenerative Disease Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030

Table 6. Global Neurodegenerative Disease Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030

Table 7. Global Neurodegenerative Disease Market Size by Region (2019-2024) & (US$ Million)

Table 8. Global Neurodegenerative Disease Market Share by Region (2019-2024)

Table 9. Global Neurodegenerative Disease Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 10. Global Neurodegenerative Disease Market Share by Region (2025-2030)

Table 11. Neurodegenerative Disease Market Trends

Table 12. Neurodegenerative Disease Market Drivers

Table 13. Neurodegenerative Disease Market Challenges

Table 14. Neurodegenerative Disease Market Restraints

Table 15. Global Neurodegenerative Disease Revenue by Players (2019-2024) & (US$ Million)

Table 16. Global Neurodegenerative Disease Revenue Share by Players (2019-2024)

Table 17. Global Top Neurodegenerative Disease by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disease as of 2023)

Table 18. Global Neurodegenerative Disease Industry Ranking 2022 VS 2023 VS 2024

Table 19. Global 5 Largest Players Market Share by Neurodegenerative Disease Revenue (CR5 and HHI) & (2019-2024)

Table 20. Global Key Players of Neurodegenerative Disease, Headquarters and Area Served

Table 21. Global Key Players of Neurodegenerative Disease, Product and Application

Table 22. Global Key Players of Neurodegenerative Disease, Product and Application

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Neurodegenerative Disease Market Size by Type (2019-2024) & (US$ Million)

Table 25. Global Neurodegenerative Disease Revenue Market Share by Type (2019-2024)

Table 26. Global Neurodegenerative Disease Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 27. Global Neurodegenerative Disease Revenue Market Share by Type (2025-2030)

Table 28. Global Neurodegenerative Disease Market Size by Application (2019-2024) & (US$ Million)

Table 29. Global Neurodegenerative Disease Revenue Share by Application (2019-2024)

Table 30. Global Neurodegenerative Disease Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 31. Global Neurodegenerative Disease Revenue Share by Application (2025-2030)

Table 32. North America Neurodegenerative Disease Market Size by Type (2019-2024) & (US$ Million)

Table 33. North America Neurodegenerative Disease Market Size by Type (2025-2030) & (US$ Million)

Table 34. North America Neurodegenerative Disease Market Size by Application (2019-2024) & (US$ Million)

Table 35. North America Neurodegenerative Disease Market Size by Application (2025-2030) & (US$ Million)

Table 36. North America Neurodegenerative Disease Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 37. North America Neurodegenerative Disease Market Size by Country (2019-2024) & (US$ Million)

Table 38. North America Neurodegenerative Disease Market Size by Country (2025-2030) & (US$ Million)

Table 39. Europe Neurodegenerative Disease Market Size by Type (2019-2024) & (US$ Million)

Table 40. Europe Neurodegenerative Disease Market Size by Type (2025-2030) & (US$ Million)

Table 41. Europe Neurodegenerative Disease Market Size by Application (2019-2024) & (US$ Million)

Table 42. Europe Neurodegenerative Disease Market Size by Application (2025-2030) & (US$ Million)

Table 43. Europe Neurodegenerative Disease Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 44. Europe Neurodegenerative Disease Market Size by Country (2019-2024) & (US$ Million)

Table 45. Europe Neurodegenerative Disease Market Size by Country (2025-2030) & (US$ Million)

Table 46. China Neurodegenerative Disease Market Size by Type (2019-2024) & (US$ Million)

Table 47. China Neurodegenerative Disease Market Size by Type (2025-2030) & (US$ Million)

Table 48. China Neurodegenerative Disease Market Size by Application (2019-2024) & (US$ Million)

Table 49. China Neurodegenerative Disease Market Size by Application (2025-2030) & (US$ Million)

Table 50. Asia Neurodegenerative Disease Market Size by Type (2019-2024) & (US$ Million)

Table 51. Asia Neurodegenerative Disease Market Size by Type (2025-2030) & (US$ Million)

Table 52. Asia Neurodegenerative Disease Market Size by Application (2019-2024) & (US$ Million)

Table 53. Asia Neurodegenerative Disease Market Size by Application (2025-2030) & (US$ Million)

Table 54. Asia Neurodegenerative Disease Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030

Table 55. Asia Neurodegenerative Disease Market Size by Region (2019-2024) & (US$ Million)

Table 56. Asia Neurodegenerative Disease Market Size by Region (2025-2030) & (US$ Million)

Table 57. Middle East, Africa, and Latin America Neurodegenerative Disease Market Size by Type (2019-2024) & (US$ Million)

Table 58. Middle East, Africa, and Latin America Neurodegenerative Disease Market Size by Type (2025-2030) & (US$ Million)

Table 59. Middle East, Africa, and Latin America Neurodegenerative Disease Market Size by Application (2019-2024) & (US$ Million)

Table 60. Middle East, Africa, and Latin America Neurodegenerative Disease Market Size by Application (2025-2030) & (US$ Million)

Table 61. Middle East, Africa, and Latin America Neurodegenerative Disease Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 62. Middle East, Africa, and Latin America Neurodegenerative Disease Market Size by Country (2019-2024) & (US$ Million)

Table 63. Middle East, Africa, and Latin America Neurodegenerative Disease Market Size by Country (2025-2030) & (US$ Million)

Table 64. Novartis Company Details

Table 65. Novartis Business Overview

Table 66. Novartis Neurodegenerative Disease Product

Table 67. Novartis Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 68. Novartis Recent Developments

Table 69. Pfizer Company Details

Table 70. Pfizer Business Overview

Table 71. Pfizer Neurodegenerative Disease Product

Table 72. Pfizer Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 73. Pfizer Recent Developments

Table 74. Merck Serono Company Details

Table 75. Merck Serono Business Overview

Table 76. Merck Serono Neurodegenerative Disease Product

Table 77. Merck Serono Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 78. Merck Serono Recent Developments

Table 79. Biogen Idec Company Details

Table 80. Biogen Idec Business Overview

Table 81. Biogen Idec Neurodegenerative Disease Product

Table 82. Biogen Idec Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 83. Biogen Idec Recent Developments

Table 84. TEVA Company Details

Table 85. TEVA Business Overview

Table 86. TEVA Neurodegenerative Disease Product

Table 87. TEVA Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 88. TEVA Recent Developments

Table 89. UCB Company Details

Table 90. UCB Business Overview

Table 91. UCB Neurodegenerative Disease Product

Table 92. UCB Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 93. UCB Recent Developments

Table 94. Boehringer Ingelheim Company Details

Table 95. Boehringer Ingelheim Business Overview

Table 96. Boehringer Ingelheim Neurodegenerative Disease Product

Table 97. Boehringer Ingelheim Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 98. Boehringer Ingelheim Recent Developments

Table 99. Sanofi Company Details

Table 100. Sanofi Business Overview

Table 101. Sanofi Neurodegenerative Disease Product

Table 102. Sanofi Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 103. Sanofi Recent Developments

Table 104. GlaxoSmithKline Company Details

Table 105. GlaxoSmithKline Business Overview

Table 106. GlaxoSmithKline Neurodegenerative Disease Product

Table 107. GlaxoSmithKline Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 108. GlaxoSmithKline Recent Developments

Table 109. Livzon Pharmaceutical Company Details

Table 110. Livzon Pharmaceutical Business Overview

Table 111. Livzon Pharmaceutical Neurodegenerative Disease Product

Table 112. Livzon Pharmaceutical Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 113. Livzon Pharmaceutical Recent Developments

Table 114. Haisco Pharmaceutical Company Details

Table 115. Haisco Pharmaceutical Business Overview

Table 116. Haisco Pharmaceutical Neurodegenerative Disease Product

Table 117. Haisco Pharmaceutical Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 118. Haisco Pharmaceutical Recent Developments

Table 119. Jingxin Pharmaceutical Company Details

Table 120. Jingxin Pharmaceutical Business Overview

Table 121. Jingxin Pharmaceutical Neurodegenerative Disease Product

Table 122. Jingxin Pharmaceutical Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 123. Jingxin Pharmaceutical Recent Developments

Table 124. Dongcheng Biochemicals Company Details

Table 125. Dongcheng Biochemicals Business Overview

Table 126. Dongcheng Biochemicals Neurodegenerative Disease Product

Table 127. Dongcheng Biochemicals Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 128. Dongcheng Biochemicals Recent Developments

Table 129. Hisun Pharmaceutical Company Details

Table 130. Hisun Pharmaceutical Business Overview

Table 131. Hisun Pharmaceutical Neurodegenerative Disease Product

Table 132. Hisun Pharmaceutical Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 133. Hisun Pharmaceutical Recent Developments

Table 134. Luye Pharma Company Details

Table 135. Luye Pharma Business Overview

Table 136. Luye Pharma Neurodegenerative Disease Product

Table 137. Luye Pharma Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 138. Luye Pharma Recent Developments

Table 139. Ark Pharmaceutical Company Details

Table 140. Ark Pharmaceutical Business Overview

Table 141. Ark Pharmaceutical Neurodegenerative Disease Product

Table 142. Ark Pharmaceutical Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 143. Ark Pharmaceutical Recent Developments

Table 144. Kanghong Pharmaceutical Company Details

Table 145. Kanghong Pharmaceutical Business Overview

Table 146. Kanghong Pharmaceutical Neurodegenerative Disease Product

Table 147. Kanghong Pharmaceutical Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 148. Kanghong Pharmaceutical Recent Developments

Table 149. Huahai Pharmaceutical Company Details

Table 150. Huahai Pharmaceutical Business Overview

Table 151. Huahai Pharmaceutical Neurodegenerative Disease Product

Table 152. Huahai Pharmaceutical Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 153. Huahai Pharmaceutical Recent Developments

Table 154. BORA PHARMACEUTICALS Company Details

Table 155. BORA PHARMACEUTICALS Business Overview

Table 156. BORA PHARMACEUTICALS Neurodegenerative Disease Product

Table 157. BORA PHARMACEUTICALS Revenue in Neurodegenerative Disease Business (2019-2024) & (US$ Million)

Table 158. BORA PHARMACEUTICALS Recent Developments

Table 159. Research Programs/Design for This Report

Table 160. Key Data Information from Secondary Sources

Table 161. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Neurodegenerative Disease Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)

Figure 2. Global Neurodegenerative Disease Market Share by Type: 2023 VS 2030

Figure 3. NMDA Features

Figure 4. SSRIs Features

Figure 5. Dopamine Inhibitors Features

Figure 6. Global Neurodegenerative Disease Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)

Figure 7. Global Neurodegenerative Disease Market Share by Application: 2023 VS 2030

Figure 8. Parkinson’s Disease Case Studies

Figure 9. Huntington Disease Case Studies

Figure 10. Amyotrophic Lateral Sclerosis Case Studies

Figure 11. Alzheimer’s Disease Case Studies

Figure 12. Neurodegenerative Disease Report Years Considered

Figure 13. Global Neurodegenerative Disease Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 14. Global Neurodegenerative Disease Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 15. Global Neurodegenerative Disease Market Share by Region: 2023 VS 2030

Figure 16. Global Neurodegenerative Disease Market Share by Players in 2023

Figure 17. Global Top Neurodegenerative Disease Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disease as of 2023)

Figure 18. The Top 10 and 5 Players Market Share by Neurodegenerative Disease Revenue in 2023

Figure 19. North America Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 20. North America Neurodegenerative Disease Market Share by Type (2019-2030)

Figure 21. North America Neurodegenerative Disease Market Share by Application (2019-2030)

Figure 22. North America Neurodegenerative Disease Market Share by Country (2019-2030)

Figure 23. United States Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. Canada Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. Europe Neurodegenerative Disease Market Size YoY (2019-2030) & (US$ Million)

Figure 26. Europe Neurodegenerative Disease Market Share by Type (2019-2030)

Figure 27. Europe Neurodegenerative Disease Market Share by Application (2019-2030)

Figure 28. Europe Neurodegenerative Disease Market Share by Country (2019-2030)

Figure 29. Germany Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. France Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. U.K. Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Italy Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Russia Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Nordic Countries Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. China Neurodegenerative Disease Market Size YoY (2019-2030) & (US$ Million)

Figure 36. China Neurodegenerative Disease Market Share by Type (2019-2030)

Figure 37. China Neurodegenerative Disease Market Share by Application (2019-2030)

Figure 38. Asia Neurodegenerative Disease Market Size YoY (2019-2030) & (US$ Million)

Figure 39. Asia Neurodegenerative Disease Market Share by Type (2019-2030)

Figure 40. Asia Neurodegenerative Disease Market Share by Application (2019-2030)

Figure 41. Asia Neurodegenerative Disease Market Share by Region (2019-2030)

Figure 42. Japan Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. South Korea Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. China Taiwan Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Southeast Asia Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. India Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. Australia Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 48. Middle East, Africa, and Latin America Neurodegenerative Disease Market Size YoY (2019-2030) & (US$ Million)

Figure 49. Middle East, Africa, and Latin America Neurodegenerative Disease Market Share by Type (2019-2030)

Figure 50. Middle East, Africa, and Latin America Neurodegenerative Disease Market Share by Application (2019-2030)

Figure 51. Middle East, Africa, and Latin America Neurodegenerative Disease Market Share by Country (2019-2030)

Figure 52. Brazil Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 53. Mexico Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 54. Turkey Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 55. Saudi Arabia Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 56. Israel Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 57. GCC Countries Neurodegenerative Disease Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 58. Novartis Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 59. Pfizer Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 60. Merck Serono Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 61. Biogen Idec Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 62. TEVA Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 63. UCB Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 64. Boehringer Ingelheim Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 65. Sanofi Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 66. GlaxoSmithKline Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 67. Livzon Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 68. Haisco Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 69. Jingxin Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 70. Dongcheng Biochemicals Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 71. Hisun Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 72. Luye Pharma Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 73. Ark Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 74. Kanghong Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 75. Huahai Pharmaceutical Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 76. BORA PHARMACEUTICALS Revenue Growth Rate in Neurodegenerative Disease Business (2019-2024)

Figure 77. Bottom-up and Top-down Approaches for This Report

Figure 78. Data Triangulation

Figure 79. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Autism Intervention Software Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-37O18689

Wed Dec 11 00:00:00 UTC 2024

Add to Cart

D-Amphetamine Sulfate API - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-0I12614

Fri Dec 06 00:00:00 UTC 2024

Add to Cart

Relapsing-Remitting Multiple Sclerosis - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-19Z9868

Wed Dec 04 00:00:00 UTC 2024

Add to Cart

ADHD Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-27T10171

Tue Dec 03 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions